Continuous Glucose Monitoring Frequency and Glycemic Control in People With Type 2 Diabetes
JAMA Network Open 10.1001/jamanetworkopen.2025.39278October 31, 2025 at 11:00 AM EDT
Is frequent continuous glucose monitoring (CGM) use associated with hemoglobin A (HbA) across different medications among people with type 2 diabetes?In this cross-sectional study of 9258 adults with type 2 diabetes, patients with the highest CGM frequency (>270 days of sensor use) during the 12 months after acquiring a CGM sensor achieved greater HbA reductions vs no CGM regardless of different medications.This study found that continuous use of CGM (>75% of days) improves glycemic control compared with less frequent or no CGM, suggesting that 6 months post–CGM initiation may be a critical time to focus counseling on continuing CGM use.
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Need more information? Contact us.